SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharma gets partial relief from US court in litigation involving three generic drugs

03 Dec 2019 Evaluate

Sun Pharmaceutical Industries has received partial relief from a US court in a litigation alleging delay by the company in launching three generic drugs in the American market. The company is a defendant in a multi-district litigation brought by various classes of plaintiffs in the US District Court (District of Massachusetts), alleging a delay in the market entry for three generic drugs -- Valganciclovir, Valsartan and Esomeprazole.

Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.

Sun Pharma Inds. Share Price

1825.35 17.15 (0.95%)
04-May-2026 09:10 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1825.35
Dr. Reddys Lab 1315.20
Cipla 1315.60
Zydus Lifesciences 904.55
Lupin 2328.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×